Jotbody -Beyond Affinity-’s Post

𝗟𝗶𝗴𝗵𝘁-𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗶𝘃𝗲 𝗮𝗻𝗱 𝗗𝘂𝗮𝗹-𝗧𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗟𝗶𝗽𝗼𝘀𝗼𝗺𝗲𝘀: 𝗙𝗿𝗼𝗺 𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺𝘀 𝘁𝗼 𝗧𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀 In recent years, nanocarriers have played an ever-increasing role in clinical and biomedical applications owing to their unique physicochemical properties and surface functionalities. Lately, much effort has been directed towards the development of smart, stimuli-responsive nanocarriers that are capable of releasing their cargos in response to specific stimuli. These intelligent-responsive nanocarriers can be further surface-functionalized so as to achieve active tumor targeting in a sequential manner, which can be simply modulated by the stimuli. Continue reading here: https://lnkd.in/dqeJxzbK #excipinets #liposomes

Are you looking to leverage the advantages of Exosome application, from discovery, to manufacturing, to commercialization? Then look no further than Exosomes Europe, the go-to event for anyone looking to advance their EV research. 📍 DoubleTree Tower of London 💻 Sessions available digitally 📅 5-6 of June 💲 Buy Two Passes, Get One Free* 🌐 Book Now: https://bit.ly/49xSPGV Hear from Founder & CEO of Mursla Bio, Pierre Arsène as he discusses the quest for the 'killer application' of EV products, and answers all your burning questions such as:   🔻 Why hasn't the first 'Killer Application' in EV modality emerged yet? 🔻 What could be missing on the path towards that? 🔻 Which applications are leading the way in Therapeutics, Diagnostics and beyond. 🔻 What are the future perspectives and emerging directions in the EV space? PLUS, we'll help you on the path to exosome success, with in-depth case studies and innovative new data on using EVs for regenerative medicine, skin rejuvenation, cancer treatments, cell-specific cargo delivery & vaccines, genetic therapies, spinal cord injuries, orthopedics and more!   You're spoilt for choice, so book now & don't miss out on hearing direct from those on the front lines of exosome research! PLUS, we're now offering buy two get one free*, so you can upscale the whole team for less! Learn More: https://bit.ly/3T8Pwif *T&Cs on website #Exosomes #ExosomesEurope #ApplicationsOfExosomes #extracellularvesicles #biopharma #pharma #bioprocessing #bioprocess #bioprocessinternational #hybrid #hybridevent #informa #informaconnect

We deliver infinite solutions to manufacturing workflows. Our Infinity MTx™ cellular engineering platform limits the need for specific payloads, media, and complex buffers to accomplish complex editing protocols. Fewer parameters enables streamlined optimization that is directly transferrable between low and high volume - allowing cell therapy workflows to seamlessly scale from research to commercial to clinical. See how it works: https://lnkd.in/ebTRuw2e #microfluidics #innovation #celltherapy #tcells #NKcells #regenerativemedicine #cancer #cancerresearch #geneediting #complexediting #sequentialediting

Global #Thyroid #Ablation #Devices Market: By Type (Radiofrequency Ablation, Microwave Ablation, Others), By Product (Thermal-based Devices, Non-thermal-based Devices), By Application (Thyroid Cancer, Thyroid Nodules), By End Use (Hospitals, Ambulatory Surgical Centers, Cancer Specialty Centers, Others) and Region : Cumulative Growth Opportunities Analysis, Size, Share, Trends, and Industry Forecast Till 2030. By: Analytical Market Research Read More Info:https://lnkd.in/dK74bjV6 Key Players: Theraclion, Terumo Blood and Cell Technologies , starMed Co. Ltd., Olympus Corporation., MedWaves., Medtronic Plc., Johnson & Johnson, Integra LifeSciences , BVM Medical , etc. #marketgrowth #marketshare #marketsize #marketdemands #marketforecast #marketstretargy #marketanalysis #markettrends #market

At Psephos we are proud to be working with a wide variety of clients, from start-ups to multinationals, many of whom are focusing on exciting new technologies. A number of our current clients are developing innovative uses for advanced ablation devices: from pioneering a patented catheter which will redefine the cornerstone of AF ablation to microwave ablation in oncology applications; from “traditional” energy sources to novel generators and methods; from cardiac to respiratory applications and beyond. We have a team of specialists who can support you with the most appropriate regulatory and clinical strategies for your innovative technology.  Contact us to find out more at info@psephos.com #medtech #cardiacablation #ablation #oncology #regulatorycompliance #regulatorystrategy #clinicalstrategy

Nanomedicine: A New Era in Precision Health Nanomedicine is transforming the landscape of disease treatment through groundbreaking innovations like targeted therapies, personalized drug delivery, and wearable diagnostics. By harnessing advanced technologies such as stimuli-responsive nanoparticles and electrochemical sensors, these treatments can precisely target affected tissues, significantly reducing side effects on healthy cells. This innovative approach holds immense promise for managing conditions such as cancer, genetic disorders, and chronic diseases, offering customized treatments alongside real-time monitoring for optimal patient outcomes. As the field progresses, nanomedicine is poised to become a cornerstone of precision medicine, enhancing both treatment efficacy and patient care. Chosen by @Lena Qawasmi #PersonalizedMedicine #Nanomedicine #PrecisionMedicine #Innovations https://lnkd.in/dAQ-aa28

Global Database of Exosome Companies, 2024 -https://lnkd.in/ezHg2Pc The world’s only database of companies that specialize in developing exosome therapies, diagnostics, and platform technologies. Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells. In recent years, exosomes have been gaining momentum as a strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering cells to patients. With at least 33,886 scientific articles published about exosomes and at least 403 clinical trials, these small vesicles have intriguing potential to be used across a range of therapeutic applications. This database features all known companies worldwide who specialize in developing exosome and extracellular vesicle (EV) therapies, diagnostics, and platform technologies. It takes our team of analysts hours of exhaustive research to uncover these exosome and EV companies from across the globe, but thankfully, we have a talented and multilingual team who is up to the task. Use this database of exosome companies to: 1. Identify global competitors within the exosome marketplace 2. Learn about technologies being developed by exosome market leaders 3. Identify regions that are “hotspots” for exosome therapies 4. Identify M&A activity within the exosome industry Because this database is an essential resource within our company, we are confident you will find it to be a valuable resource too. This week only, you can claim this global database for $100 off. #exosomes #extracellularvesicles #advancedtherapies #regenerativemedicine

After welcoming over 80 participants to our inaugural PluriCon 2024 event back on Sept 10, 2024, Pluristyx, Inc. is thrilled to announce PluriCon 2024 PostScript: a series of posts sharing insights from our speakers. A common theme was the risk of using an inconsistent iPSC starting material both from the perspective of patient safety as well as in the development of a robust and scalable manufacturing process. Over the next few weeks, Pluristyx will be sharing thoughts from select PluriCon 2024 speakers on developing strategies to de-risk iPSCs as a starting material for regenerative medicine therapies.   💠 Translating Today’s Discoveries into Tomorrow’s Therapies - Observations and experiences in the complexities of translating cell therapies to industry with an emphasis on continuous improvement and optimization of the manufacturing process. 💠 Designing a Better Cell Therapy – Novel technologies for iPSC differentiation to address cost, consistency and scalability challenges. 💠 Testing for Success – Creating robust iPSC lines suitable for clinical applications by developing strategies around improving testing methods and optimizing workflows to identify loss of genetic integrity.    💠 Culture Consistency – Understanding variability in iPSC cell culture to minimize stressors and develop a controlled, reproducible and cost-effective paradigm for iPSC culture and cryopreservation.   💠 Developing an iPSC-based clinical therapy – A case study in overcoming the challenges of developing an iPSC-based therapy including conducting extensive genomic analysis to ensure safety, freedom to operate and IP considerations. 💠 Regulatory Challenges and Opportunities – Insights into the regulatory landscape for iPSC-based therapies centered around the risk-reward calculus of regulatory expectations vs. risk management.   💠 Cryopreservation Considerations for iPSC-derived products – An often under appreciated and overlooked step in the manufacturing process, cryopreservation is often a hidden hurdle towards commercialization.    We hope that these posts will spark discussions between regulators, therapy developers, and academics on existing challenges in using iPSCs for clinical development.  Stay up to date as we release weekly deep dives into these critical topics to continue the conversation in developing Tomorrow’s Cell Therapies, Today®: https://lnkd.in/g99f-vE6     #PluriCon2024 #StemCells #Celltherapy #iPSC

😎 It's tomorrow! Don't miss the webinar "Drug Response Profiling of Primary Colorectal Tumor Models using spheroONE Pu·MA System EC". This webinar is a collaborative effort between PFI, MatTek Life Sciences, SCIENION, and Cellenion. 🚀🔬 Primary tumoroids are sorted & dispensed into flowchips for drug testing using phenotypic assays. Automated compound incubation and viability staining lead to consistent reproducible high-quality data. This platform is a valuable tool in a wide range of research areas enabling multiplex disease modeling, drug discovery and personalized medicine. 📅 Date: May 29, 2024 🕒 Time: 8 am PDT / 11 am EDT / 5 pm CET 📍 Register here: https://lnkd.in/grHujeWu Register now! #webinar #spheroids #organoids #tumoroids #3dcellularmodels #flowchips #microfluidics #drugtesting #automation

𝗛𝗼𝘄 𝗦𝗰𝗮𝗹𝗶𝗻𝗴 𝗛𝗲𝗮𝗿𝘁 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 (𝗖𝗮𝗿𝗱𝗶𝗼𝗺𝘆𝗼𝗰𝘆𝘁𝗲𝘀) 𝗳𝗿𝗼𝗺 𝟮𝗗 𝘁𝗼 𝟯𝗗 𝗦𝗮𝘃𝗲𝘀 𝗟𝗶𝘃𝗲𝘀 💖 As part of an initial proof of concept for a scalable production process in organoid-based heart cell therapy, we cultivated 𝘪𝘗𝘚𝘊-𝘥𝘦𝘳𝘪𝘷𝘦𝘥 𝘤𝘢𝘳𝘥𝘪𝘰𝘮𝘺𝘰𝘤𝘺𝘵𝘦𝘴 (CMs) at a 2L scale. These iPSC-derived CMs can act as “microtissues,” with potential applications in replacing cardiac tissue lost due to myocardial infarction. Each treatment requires approximately 𝟴 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗰𝗲𝗹𝗹𝘀 per dose 🫀, leading to an estimated global annual need of over 𝟮𝟰 𝗾𝘂𝗮𝗱𝗿𝗶𝗹𝗹𝗶𝗼𝗻 𝗰𝗲𝗹𝗹𝘀 🌍—an amount current technology cannot yet meet. Our mission? To make these life-saving therapies widely available by providing the first scalable low-shear bioreactor ⚙️. PS. Those aren't bubbles in our bioreactors, but cells! #BioThrust #Organoids #Cardiomyocytes #CellTherapy #iPSC